a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.
Inhibikase Therapeutics Announces First P... - Cure Parkinson's
Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
4 Replies
•
Is this a similar drug to nilotinib?
Do not know about the chemistry but they are apparently aiming for a similar effect. They reference some nilotinib research in their list of publications:
Thanks for sharing!
Not what you're looking for?
You may also like...
Dry Mouth, Gum Disease, Chapped Lips, Dry Eyes, Dry Skin, Eye Floaters And Some Possible Help From A Single Spray!
With winter just around the corner, this information may be most useful and timely! With winter...
Dopamine Dysregulation Syndrome
Definition here;
https://en.m.wikipedia.org/wiki/Dopamine_dysregulation_syndrome
How can docs be...
In Pursuit Of Restful Sleep And Help For Nocturia
One topic that seems to come up regularly on this forum is the issue of poor sleep or insomnia and...
If we accept that PD is basically a metabolic dysfunction...then electrolytes
The metabolic dysfunction theory as I understand it, states that the energy production factories...
Adding Sinemet to Mucuna
We're trying to go in the opposite direction of many here by adding Sinemet to Mucuna and are...
Related Posts
- How To Make Melatonin Lotion : A More Efficient Way Of Getting Melatonin Compared To Oral Melatonin And A Surprise Finding
Carnivore Diet - Can't solidly recommend it
Optimising LD timings
Dr. Greger's view on NAD supplementation
New Clinical Trial Starting: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) (REGENERATE-PD)
